Literature DB >> 7567751

Cardioversion of atrial fibrillation.

G Y Lip1.   

Abstract

Cardioversion to sinus rhythm should be considered for all patients in atrial fibrillation in order to improve cardiac performance and perhaps to reduce the long-term risk of thromboembolic complications. Different methods of cardioversion, whether electrical or pharmacological, exist and there is often uncertainty about performing the procedure. In particular, there is often confusion about the use of anti-arrhythmic drugs and the suitable length of anticoagulant therapy required pre- and post-cardioversion. This review discusses the current understanding of electrical and pharmacological cardioversion of atrial fibrillation, the clinical effects and the role of prophylactic anti-arrhythmic and anticoagulant therapy in this procedure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7567751      PMCID: PMC2398208          DOI: 10.1136/pgmj.71.838.457

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  65 in total

1.  Left ventricular function in patients with atrial fibrillation before and after cardioversion.

Authors:  M Alam; C Thorstrand
Journal:  Am J Cardiol       Date:  1992-03-01       Impact factor: 2.778

Review 2.  Management of atrial fibrillation.

Authors:  E L Pritchett
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

3.  Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter.

Authors:  A T Gosselink; H J Crijns; I C Van Gelder; H Hillige; A C Wiesfeld; K I Lie
Journal:  JAMA       Date:  1992-06-24       Impact factor: 56.272

4.  Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.

Authors:  E Grey; D I Silverman
Journal:  Pacing Clin Electrophysiol       Date:  1993-12       Impact factor: 1.976

Review 5.  The optimal technique for electrical cardioversion of atrial fibrillation.

Authors:  G A Ewy
Journal:  Clin Cardiol       Date:  1994-02       Impact factor: 2.882

6.  Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation.

Authors:  W J Manning; D I Silverman; S E Katz; M F Riley; P C Come; R M Doherty; J T Munson; P S Douglas
Journal:  J Am Coll Cardiol       Date:  1994-06       Impact factor: 24.094

7.  Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter.

Authors:  A Z Arnold; M J Mick; R P Mazurek; F D Loop; R G Trohman
Journal:  J Am Coll Cardiol       Date:  1992-03-15       Impact factor: 24.094

8.  Hematologic correlates of spontaneous echo contrast in patients with atrial fibrillation and implications for thromboembolic risk.

Authors:  D Fatkin; E Herbert; M P Feneley
Journal:  Am J Cardiol       Date:  1994-04-01       Impact factor: 2.778

9.  Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study.

Authors:  M F Stoddard; P R Dawkins; C R Prince; N M Ammash
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

10.  Functional capacity before and after cardioversion of atrial fibrillation: a controlled study.

Authors:  A T Gosselink; H J Crijns; M P van den Berg; S A van den Broek; H Hillege; M L Landsman; K I Lie
Journal:  Br Heart J       Date:  1994-08
View more
  12 in total

Review 1.  Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation.

Authors:  R H Foster; M I Wilde; A Markham
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 2.  Rhythm control and cardioversion.

Authors:  N Sulke; F Sayers; G Y H Lip
Journal:  Heart       Date:  2006-09-08       Impact factor: 5.994

3.  Cardioversion of atrial fibrillation.

Authors:  O M Jolobe
Journal:  Postgrad Med J       Date:  1996-02       Impact factor: 2.401

Review 4.  WITHDRAWN: Pharmacological cardioversion for atrial fibrillation and flutter.

Authors:  John Cordina; Gillian E Mead
Journal:  Cochrane Database Syst Rev       Date:  2017-11-15

Review 5.  WITHDRAWN: Electrical cardioversion for atrial fibrillation and flutter.

Authors:  Gillian E Mead; Andrew Elder; Andrew D Flapan; John Cordina
Journal:  Cochrane Database Syst Rev       Date:  2017-11-15

6.  A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project.

Authors:  G Y Lip; D J Golding; M Nazir; D G Beevers; D L Child; R I Fletcher
Journal:  Br J Gen Pract       Date:  1997-05       Impact factor: 5.386

7.  Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation.

Authors:  Andreas Goette; Hein Heidbuchel
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

8.  Direct current cardioversion does not cause cardiac damage: evidence from cardiac troponin T estimation.

Authors:  A C Rao; N Naeem; C John; P O Collinson; R Canepa-Anson; S P Joseph
Journal:  Heart       Date:  1998-09       Impact factor: 5.994

9.  Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) randomized trial.

Authors:  Gregory Y H Lip; Jose L Merino; Maciej Banach; Naab Al-Saady; James Jin; Michael Melino; Shannon M Winters; Monika Kozieł; Andreas Goette
Journal:  J Arrhythm       Date:  2020-04-15

10.  Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure.

Authors:  Axel Brandes; Harry J G M Crijns; Michiel Rienstra; Paulus Kirchhof; Erik L Grove; Kenneth Bruun Pedersen; Isabelle C Van Gelder
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.